MaaT Pharma SA

DB:4RD Stock Report

Market Cap: €110.2m

MaaT Pharma Valuation

Is 4RD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4RD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 4RD's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 4RD's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4RD?

Key metric: As 4RD is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 4RD. This is calculated by dividing 4RD's market cap by their current revenue.
What is 4RD's PS Ratio?
PS Ratio42.9x
Sales€2.57m
Market Cap€110.23m

Price to Sales Ratio vs Peers

How does 4RD's PS Ratio compare to its peers?

The above table shows the PS ratio for 4RD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.3x
2INV 2invest
8.2xn/a€63.8m
HPHA Heidelberg Pharma
12.3x16.6%€103.9m
FYB Formycon
13.6x33.4%€827.2m
MDG1 Medigene
3x16.1%€22.6m
4RD MaaT Pharma
42.9x59.7%€110.2m

Price-To-Sales vs Peers: 4RD is expensive based on its Price-To-Sales Ratio (42.9x) compared to the peer average (9.2x).

Price to Sales Ratio vs Industry

How does 4RD's PS Ratio compare vs other companies in the DE Biotechs Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
V9Z Aceragen
0.3x-161.8%US$2.18m
4RD 42.9xIndustry Avg. 8.0xNo. of Companies6PS0612182430+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 4RD is expensive based on its Price-To-Sales Ratio (42.9x) compared to the European Biotechs industry average (7.9x).

Price to Sales Ratio vs Fair Ratio

What is 4RD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4RD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio42.9x
Fair PS Ratio9.2x

Price-To-Sales vs Fair Ratio: 4RD is expensive based on its Price-To-Sales Ratio (42.9x) compared to the estimated Fair Price-To-Sales Ratio (9.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 4RD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€7.20
€16.20
+125.0%
17.9%€21.00€13.80n/a4
Nov ’25€6.94
€14.95
+115.4%
7.0%€16.00€13.80n/a4
Oct ’25€7.02
€14.95
+113.0%
7.0%€16.00€13.80n/a4
Sep ’25€6.84
€14.95
+118.6%
7.0%€16.00€13.80n/a4
Aug ’25€7.04
€14.95
+112.4%
7.0%€16.00€13.80n/a4
Jul ’25€6.94
€14.95
+115.4%
7.0%€16.00€13.80n/a4
Jun ’25€7.56
€14.60
+93.1%
6.8%€16.00€13.80n/a3
May ’25€8.84
€15.50
+75.3%
2.6%€16.00€15.00n/a3
Apr ’25€8.64
€15.25
+76.5%
1.6%€15.50€15.00n/a2
Mar ’25€7.54
€15.25
+102.3%
1.6%€15.50€15.00n/a2
Feb ’25€6.80
€15.25
+124.3%
1.6%€15.50€15.00n/a2
Jan ’25€6.38
€15.25
+139.0%
1.6%€15.50€15.00n/a2
Dec ’24€6.24
€15.25
+144.4%
1.6%€15.50€15.00n/a2
Nov ’24€7.46
€15.25
+104.4%
1.6%€15.50€15.00€6.942
Oct ’24€4.88
€15.25
+212.5%
1.6%€15.50€15.00€7.022
Sep ’24€6.30
€15.50
+146.0%
3.2%€16.00€15.00€6.842
Aug ’24€6.36
€15.50
+143.7%
3.2%€16.00€15.00€7.042
Jan ’24€7.92
€19.30
+143.7%
1.6%€19.60€19.00€6.382
Dec ’23€9.12
€19.30
+111.6%
1.6%€19.60€19.00€6.242
Nov ’23€8.74
€19.30
+120.8%
1.6%€19.60€19.00€7.462

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Regeneron Pharmaceuticals

US$80.0b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

RGO

US$705.00

7D

-7.1%

1Y

-3.8%

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.60

7D

-6.2%

1Y

90.0%

Merck

US$246.5b

Operates as a healthcare company worldwide.

6MK

US$93.40

7D

0.3%

1Y

-0.4%